NeuroproteXeon
www.neuroprotexeon.comNeuroproteXeon is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death following acute neurologic injury. NP is currently preparing for a Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA).
Read more
NeuroproteXeon is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to protect against brain cell death following acute neurologic injury. NP is currently preparing for a Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA).
Read more
Country
State
New York
Industry
Employees
11-50
Founded
2015
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Director of Operations
Email ****** @****.comPhone (***) ****-****
Reach decision makers at NeuroproteXeon
Free credits every month!
NeuroproteXeon FAQ
United States
Pharmaceutical Manufacturing
